IAS–USA Course Features Doravirine/Islatravir Following FDA Approval

The US Food and Drug Administration has approved doravirine 100 mg/islatravir 0.25 mg, a once-daily, single-tablet, 2-drug regimen for adults with virologically suppressed HIV-1. The regimen is indicated for individuals who have maintained viral suppression for at least 3 months, with no history of treatment failure or known resistance to doravirine. In phase III trials, the combination maintained viral suppression at rates comparable to standard 3-drug therapies through 48 weeks, with a generally favorable safety profile. As the first nonnucleoside reverse transcriptase inhibitor (NNRTI)-based, tenofovir-free, 2-drug regimen, this approval provides a simplified treatment option for eligible patients. This combination was also discussed in a recent IAS-USA course in Atlanta, including a presentation by Rajesh Gandhi and a case presentation by Michael Saag.